GSTP1 and myelodysplastic syndrome: Ezatiostat is the first GSTP1-1 inhibitor shown to cause clinically significant reductions in RBC and platelet transfusions, including transfusion independence, as well as trilineage hematologic improvement—HI-E, HI-N and HI-P—in single-agent monotherapy trials in patients with IPSS Low or Intermediate-1 risk MDS [7,14,15], thereby providing a unique profile of activity in MDS.